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ABSTRACT 
BACKGROUND: Now considered a cornerstone of healthcare, patient-provider 
communication has long been studied and analyzed. Medical associations such as the 
Joint Commission and the American Association of Orthopaedic Surgeons (AAOS) have 
strongly endorsed for physicians to exercise patient-focused communication, a practice 
that involves showing empathy, involving patients in medical care decisions, eliciting 
concerns, and educating patients on treatment options (Joint Commission, 2016; AAOS, 
2017).  
A lack of patient-provider communication has previously been identified as a 
significant factor in adverse medical outcomes occurring within hospitals (Khan et al., 
2017). Bridging the communication disparity between patients and providers is crucial to 
improving overall patient outcome. Primary care providers are especially essential to 
improving overall patient outcome because they serve as the first point of contact for 
many patients accessing the healthcare system. While there is much literature on the 
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importance of effective patient-provider communication, few studies provide technology-
based tools that can enhance this establishment of communication.  
Human Papillomavirus is presently the most common sexually transmitted 
infection (STI) nationwide with 79 million Americans currently infected (CDC, 2017). 
Approximately 42,700 HPV-attributable cancers are diagnosed in the United States 
annually, and HPV is believed to be responsible for over 90% of cervical cancer cases 
(CDC, 2018). The Advisory Committee on Immunization Practices (ACIP) currently 
recommends three preventative HPV vaccines. Despite high rates of infection, HPV 
vaccination rates nationwide remain low as coverage of the HPV vaccine falls behind that 
of coverage for required vaccines like the tetanus, diphtheria, and acellular pertussis 
vaccine (Tdap) (Reagan-Steiner, 2016). Previous studies have sought to address factors 
that affect decisions to vaccinate children. An analyzation of the National Immunization 
Survey of Teens has identified that parents’ belief that the HPV was not necessary as a 
main factor (Darden et al., 2013). As a result, there is a gap needed to be filled by 
providers to educate parents on the importance of the HPV vaccine. 
 
PURPOSE: The current study sought to determine the effectiveness of a web-based 
mobile health education program called Wheel of Wellness (WoW) on patient-provider 
communication, to assess the viability and impact of WoW to increase HPV vaccination 
rates in age eligible children (boys and girls aged 9-17) and to augment awareness about 
the benefits of HPV vaccination in both these children and their guardians.  
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RESEARCH METHOD AND DESIGN: As of August 2018, twenty-seven parents of 
children between the ages of 9 and 17 years of age within the Pediatrics and Adolescent 
departments of Boston Medical Center (BMC) have been recruited. Parents enrolled in 
the WoW program to compile a list of concerns to be shown to a provider during their 
child’s appointment. Participants were asked questions to determine initial knowledge on 
the HPV vaccine, and their opinions on the HPV vaccine. Following their appointment, 
participants completed a questionnaire to assess opinions on the WoW program in 
facilitating communication with their provider on the HPV vaccine and related cancers. 
Seven physicians were interviewed to assess their views on the WoW program in 
facilitating communication with their patients on the HPV vaccine and related cancers. 
 
RESULTS: Initial stages of this study found that views on the effectiveness of the WoW 
program in facilitating patient and provider communication on the different aspects of 
HPV vaccination and affecting parents’ decisions to vaccinate their children were mixed 
by both patients and their providers. Based on the WoW feedback collected from parents, 
the system was widely acceptable in terms of ease in usage and with the majority of 
parents (92%) reporting that the WoW website is helpful for communicating their health 
concerns with their provider. However, the majority of providers reported having never 
been presented the WoW system and expressed views that WoW was inefficient as it was 
a parallel system to existing workflow. This study determined that of the 12 participants 
who had one dose of the vaccine prior to enrollment, 75% of these participants completed 




CONCLUSION: Based on the initiation and completion statistics reported, this shows 
great potential for the use of the BNI coupled with the WoW system to help improve 
rates of initiation and completion of HPV vaccination going forward as the intervention 
may have helped encourage parents to either initiate vaccination or complete their child’s 
previously started series. Further studies should explore ways of empowering patients to 
facilitate more communication with their providers and improvements to technology to 
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 Now considered a cornerstone of healthcare, patient-provider communication has 
long been studied and analyzed. While breakthroughs in science and medical technology 
has helped to extend life expectancy worldwide, the communication between a patient 
and their provider is just as important a contributor. Many medical associations such as 
the Joint Commission and the American Association of Orthopaedic Surgeons (AAOS) 
have strongly endorsed for physicians to exercise patient-focused communication, a 
practice that involves showing empathy, involving patients in medical care decisions, 
eliciting patient concerns, honestly answering questions, informing and educating 
patients on treatment options, and demonstrating sensitivity to patients’ ethnic and 
cultural diversity (Joint Commission, 2016; AAOS, 2017).  
Physicians may be able to evaluate what they believe a patient’s condition is 
based on what can be seen immediately in person and ordered tests, but without having 
open conversations with patients, providers may not be able to identify other issues the 
patients may have that might not have fully surfaced or may suggest care treatments that 
do not match well with the patient’s lifestyle, thus resulting in less compliance and more 
detrimental health outcomes. 
 
Patient-provider communication 
Though many studies are focused on improving the advancement of medical 
science and technology to improve medical outcomes, other studies have shown that 
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simply having medical knowledge and tools are not enough to guarantee more successful 
outcomes. A lack of patient-provider communication between the parents of hospitalized 
children and their attending hospital providers has previously been identified as a 
significant factor in adverse medical outcomes occurring within hospitals (Khan et al., 
2017). While both providers and patient guardians reported miscommunications, parents 
reported miscommunications significantly more often than attending providers (16.1% to 
3.7%), showing a disparity in the perceptions on quality of communication from both 
sides (Khan et al., 2017). Likewise, a study on adherence to colorectal cancer screening 
found that perceived primary care provider relationship quality and communication with 
their patients were greatly associated with colonoscopies for cancer screening amount 
adults aged fifty years and older (Underhill and Kiviniemi, 2012). Patient participants 
who reported more positive perceptions of provider communication showed a much 
higher adherence to screening recommendations by their provider and also had reported 
higher percentages of having ever been screened for colorectal cancer (Underhill and 
Kiviniemi, 2012).  
Significant differences in the communication behaviors of primary care 
physicians with and without malpractice claims have also been identified in a previous 
study. No significant differences in communication behaviors of physicians with claims 
or no claims were identified in surgeons. However, in audiotaped interactions between 
primary care physicians (general internists, family practitioners) and their patients, 
communication behaviors were analyzed where providers without claims tended to spend 
more time soliciting patient opinions, facilitating conversation by encouraging patients to 
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talk about concerns, and educating patients on their medical understanding (Levinson W 
et al., 1997). For primary care physicians overall, these behaviors helped patients to build 
trust with their providers as they understood their conditions more and felt that their 
providers were more open in their communications with them in understanding their 
conditions and thus providing them with better care. This model for primary care 
specifically was able to improve the prediction of whether claims would be filed by 57% 
above chance, showing the effectiveness of more positive communication perception.  
 
Human Papillomavirus 
The Human Papillomavirus (HPV) is presently the most common sexually 
transmitted infection (STI) nationwide with about 79 million Americans currently 
infected and 14 million new cases of infection surfacing every year (CDC, 2017). 
Approximately 42,700 HPV-attributable cancers are diagnosed in the United States every 
year, and HPV is believed to be responsible for more than 90% of cervical cancer cases 
and about 70% of oropharynx related cancers (CDC, 2018).  
There are currently over one hundred strains of HPV that have been documented, 
and around forty of these strains are known to infect genital region mucosa (CDC, 2018). 
Different strains of HPV have been identified as being high-risk or low-risk types. HPV 
strains that are considered high-risk are those that can lead to or are responsible for most 
cases of cervical cancers such as HPV-16 and HPV-18 (CDC, 2015). HPV strains that are 
considered low-risk are those that can lead to or are responsible for most cases of genital 
warts such as HPV-6 and HPV-11 (CDC, 2015). 
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HPV is transmitted through skin-to-skin contact and is most commonly 
transmitted through vaginal or anal sex, though penetrative intercourse is not required for 
HPV infection (CDC, 2015). There are a variety of risk factors that are associated with 
the contraction of this infection such as lifetime history of sex partners, early age of 
sexual intercourse, and inconsistent condom use (Ragin et al., 2009). Most HPV cases are 
asymptomatic, however one can still develop symptoms years after one has contracted 
the virus from someone who was infected. Though there are HPV tests that can be used 
to screen women for cervical cancer, they are not recommended for screening women 
under thirty years of age and there is currently no test to determine an individual’s overall 
infection status in the mouth or throat (CDC, 2017). 
Trends in HPV associated cancers from 1999-2015 have shown that while 
cervical carcinoma rates have decreased 1.6% per year, oropharyngeal squamous cell 
carcinoma (SCC) rates have increased 2.7% per year in men and 0.8% per year in women 
(Figure 1). While the majority of HPV-associated cancers affect the cervix and cervical 
cancer was originally the leading HPV-related cancer in the U.S., oropharyngeal disease 
has been increasing in incidence and is currently surpassing cervical cancer as the leading 
HPV-related cancer in the United States (Van Dyne et al., 2018). 
	
5 
Figure 1. Trends in age-adjusted incidence of cervical carcinoma among females 
and oropharyngeal SCC among men in the United States from 1999-2015 (CDC, 
2018).  
This decline in cervical cancer from 1999-2015 has been attributed to an increase 
in cancer screening stemming back from a trend since the 1950s. However, while cervical 
cancer rates have fallen for all racial population groups overall, incidence rates among 
women identifying as black and Hispanic were still higher than women who identified as 
white in 2015, representing a disparity in the delivery of healthcare and showing how the 
healthcare needs of certain racial groups are still not being fully met (Van Dyne et al., 
2018) (Table 1). In addition, though increased cervical cancer screening has seemed to 
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aid in the decline of cervical cancer, cervical cancer screening rates among women 21-29 
years decreased from 62.8% in 2005 to 47.3% in 2016 (MacLaughlin et al., 2019). 
Table 1. Annual number, annual age-adjusted rate, and trends of HPV-associated 




The Human Papillomavirus Vaccine 
The ACIP currently recommends three preventative Food and Drug 
Administration approved HPV vaccines which include: Cervarix, a bivalent vaccine for 
HPV Types 16 and 18, Gardasil, a quadrivalent vaccine for HPV types 6, 11, 16, and 18, 
and Gardasil 9, a 9-valent vaccine for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 
(ACIP, 2015; Markowitz et al., 2014). Initiation of one of these three vaccines is 
recommended for females ages 11 or 12 years old, while initiation of either Gardasil or 
Gardasil 9 is recommended for males ages 11 or 12 years old (Meites et al., 2016). All 
three of these vaccines target the high-risk HPV types 16 and 18 that are responsible for 
most cases of cervical cancers. The most recently approved HPV vaccination, Gardasil 9, 
was approved in 2015 to account for 5 additional types of HPV strains (HPV strains 31, 
33, 45, 52, and 58) than its predecessor Gardasil. While HPV-16 and HPV-18 account for 
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approximately 64% of invasive HPV-associated cancers and 66% of cervical cancers in 
the United States, the additional five strains found in Gardasil 9 account for an additional 
10% of invasive HPV-associated cancers along with about 15% of cervical cancers 
(Saraiya et al., 2015). The other two HPV strains that both Gardasil and Gardasil 9 
vaccinate against are HPV-6 and HPV-11 which cause around 90% of anogenital warts 
and many cases of recurrent respiratory papillomatosis. These HPV-caused genital warts 
are highly infectious and have a transmission rate of 65% between sexual partners, and 
even when cleared often return within 3 months with rates up to 67% (Lacey et al., 2006).  
Previously, all three HPV vaccines were recommended to be given to patients 9-
26 years of age in a 3-dose series (Meites et al., 2016). However, more recent updates 
from the ACIP in October 2016 currently recommends for a 2-dose schedule where doses 
are given 6 months or more apart (plus or minus 4 weeks) in boys and girls who initiate 
their vaccination series between the ages of 9 through 14 years of age as multiple studies 
have shown similar high levels efficacy and effectiveness of the Gardasil 9 vaccine in 
patients between these ages regardless of a 2-dose series or a 3-dose series (where the 3-
dose series 2nd dose would be given 1-2 months after the 1st dose, and the 3rd dose would 
be given 6 months after the 1st dose) (CDC, 2016). The age cut-off for a 2-dose series is 
at 15 because of how it was found that geometric mean antibody titers were significantly 
higher in adolescents aged 9 through 15 years old when compared to adolescents aged 16 
through 26 years old (Iverson et al., 2016). However, it has also been found more 
recently from an Indian follow-up cohort study that the two-dose recommendation for the 
HPV vaccine can be extended for patients up through 18 years of age though this is not 
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currently the recommendation given by the ACIP or CDC in the United States (Basu et 
al., 2019). If a patient has not previously completed the 3-dose series, previous 
vaccination history is unknown to providers, or the patient is immunocompromised, HPV 
vaccination or vaccination completion with any available HPV vaccine product (of the 
three approved vaccines) are recommended. In addition, if a vaccination schedule is 
interrupted, the vaccination series does not need to be restarted from the first dose (CDC, 
2015). 
 
Human Papillomavirus Vaccination Rates 
Despite high rates of infection, HPV vaccination rates nationwide remain 
startlingly low as coverage of the HPV vaccine falls well behind that of coverage for 
required vaccines such as the tetanus, diphtheria, and acellular pertussis vaccine (Tdap) 
(Reagan-Steiner, 2016). In the United States as of 2017, approximately 49% of 
adolescents aged 13-17 years old were up to date on their HPV vaccines and 66% had 
received at least their first dose to start their HPV vaccination series. In the United States 
as of 2016, among females 19-26 years, 48.5% reported receiving at least one dose of the 
HPV vaccine and among males 19-26 years, 13.5% reported receiving at least one dose 
of the HPV vaccine (CDC, 2016). In the state of Massachusetts, approximately 65.5% of 
adolescents aged 13-17 years old had completed their HPV vaccination series and 81.9% 
had received at least the first dose in their HPV vaccination series, both numbers 
significantly higher than the national average (Walker et al., 2018). Though 
Massachusetts’ rate of HPV vaccination is higher than the national average however, its 
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vaccination rates still have not met the vaccination rate goal set of an 80% rate of 
vaccination for 2 or 3 doses of the HPV vaccine in adolescents aged 13 to 15 years by 
Healthy People 2020, a subset under the Office of Disease Prevention and Health 
Promotion which is managed by the United States Department of Health and Human 
Services (Healthy People 2020, 2019). 
 
Barriers to Meeting Healthy People 2020 Vaccination Goal 
One of the most prevalent barriers to HPV vaccination is parental consent. As 
adolescent patients are minors, they must obtain parental or guardian consent in order to 
receive the HPV vaccine. As a result, it is crucial to understand the factors influencing 
parental decision-making in the vaccination of their children. Previous studies have 
sought to address these factors that affect parents’ decisions to vaccinate their children 
against HPV. An analyzation of the National Immunization Survey of Teens has 
identified that parents’ belief that the HPV was not needed or not necessary as a main 
contributing factor, both due to a lack of knowledge on the vaccine and a belief that their 
children were not sexually active and thus did not need the STI-preventing vaccine 
(Darden et al., 2013). Likewise, a longitudinal study published in 2017 on the mothers of 
girls invited for HPV-vaccination found that mothers believed that HPV vaccination was 
unnecessary as many believed vaccination was less effective in preventing cervical 
cancer than having a healthy lifestyle (Pot et al., 2017).  
Another major factor that studies have tested and found associated as a barrier to 
HPV-vaccination and vaccination acceptance is a parental belief that vaccination against 
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HPV will lead to an increase in earlier risky sexual behavior in their children (Walhart, 
2012). As a result, a study done in 2006 on 1600 parents of females ages 8-12 was 
conducted to determine if increased knowledge on the vaccine would improve vaccine 
compliance by parents (Dempsey et al., 2006). In this randomized intervention study, one 
group of parents received a detailed HPV information sheet outlining HPV epidemiology 
and potential clinical outcomes of contracting the disease while another group of parents 
were handed a survey on attitudes, beliefs, and knowledge about HPV and the HPV 
vaccine. While parents who received the information sheet obtained a higher mean score 
on the following HPV knowledge assessment tool than parents who received the survey 
received, no significant statistical difference was found on the acceptability of the HPV 
vaccine between the two groups (Dempsey et. Al., 2006). 
 
Importance of Provider Recommendation  
One of the main reasons for lower HPV vaccination rates is inadequate provider 
recommendation for the vaccine. In a study on HPV vaccination series initiation and 
completion from 2008-2009, it was found that providers not recommending the vaccine 
was one of the most common reasons for parents not having their daughters vaccinated 
(13.1), a percentage almost as high as the leading reason which was due to a lack of 
knowledge of the vaccine (19.4%) (Dorell et al., 2011). Like-wise in a study on the 
differences in knowledge, attitudes, and beliefs regarding HPV vaccination between 
African-American and Haitian immigrant women, data indicated that participants 
intended to vaccinate their daughters if offered by their physicians, regardless of the low 
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levels of HPV and HPV vaccine-related knowledge that was demonstrated among the 
study’s participants (Joseph et al., 2012). Even more recently in North Carolina, thirty-
four interviews with state leaders were carried out to determine barriers to HPV 
vaccination and one of the largest barriers identified was a lack of awareness about the 
importance of HPV vaccination among the public and providers, which lead to a lack of 
provider recommendation (Cartmell et al., 2018). 
 In a study carried out by the National Immunization Survey, it was even shown 
that adolescents who received a provider recommendation for HPV vaccination were 
almost 5 times as likely to receive the vaccine as those without a recommendation 
(Ylitalo et al., 2013). While racial and ethnic minorities were less likely to receive a 
recommendation, the correlation between recommendation and vaccination remained 
strong across all racial and ethnic groups which further points to the importance to target 
health care providers with vaccine education efforts in order to increase provider 
recommendation (Ylitalo et al., 2013). 
In provider recommendation of the HPV vaccine, a study found that in 
conversations between patient parents and providers, that provider statements attesting to 
the vaccine’s value to a child did not significantly affect parental decisions to vaccinate 
their children. Rather, providers should be encouraged to state, “Your child is due for the 
HPV vaccine today” as an indicated introduction for necessity of the vaccine rather than 
introducing the vaccine as elective or contraindicated. When providers delivered an 
indicated introduction of the HPV vaccine and initially framed the HPV vaccination as a 
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“due” or “needed” vaccine, parents’ likelihood of vaccinating their children increased 
(Fenton et al., 2018). 
 
Barriers to Strong Provider Recommendation  
There is clearly a large gap needed to be filled by providers to educate parents on 
the importance of the HPV vaccine in order to dispel parents’ preconceived beliefs on the 
necessity of the vaccine and an even larger gap for providers to strongly recommend the 
HPV vaccine. The studies in the previous section prove very important points because 
they show how important provider recommendation is in the determination of whether or 
not a parent will vaccinate their child as provider recommendation is sometimes the only 
factor considered. However, studies have also found that physicians identify many 
similar concerns about the HPV vaccine that parents do and that these concerns do affect 
how strongly they recommend the HPV vaccine (Perkins & Clark, 2012). In this specific 
Perkins & Clark study on HPV vaccination for males, providers were hesitant in offering 
vaccination both because they believed that their patients’ parents would be unwilling to 
accept vaccination and also because the providers themselves were unaware of the 
serious HPV-related diseases that could occur in males (Perkins & Clark, 2012). 
Therefore, to increase vaccination rates, it seems imperative to educate providers in the 
importance of the vaccine so that they can deliver stronger recommendations for HPV 
vaccination to their patients. 
A study at Boston Medical Center trained providers to deliver a brief negotiated 
interview on HPV and the HPV vaccine with patients’ mothers in order to empower 
	
13 
providers to offer and recommend the vaccine (Joseph et al., 2016). While these brief 
negotiated interviews demonstrated increased knowledge about HPV from mothers who 
received the intervention compared to mothers who did not receive the intervention, this 
increase in knowledge did not correlate with significantly increased vaccination initiation 
or vaccination series completion rates. In addition, when listening to the audio tapes of 
conversations between providers and their patients’ mothers, it was found that some 
providers did not necessarily follow through the full negotiated interview or give all the 
information about HPV and the HPV vaccine that they initially trained to carry out 

















The current study aims to determine whether use of a web-based mobile health 
education program called Wheel of Wellness (WoW) would facilitate patient and 
provider communication on the different aspects of HPV vaccination and affect parents’ 
decisions to vaccinate their children. 
 By using the WoW system and having patients bring their concerns directly to 
their providers on their smart device, the current study aims to not only empower the 
patient and patient’s parents to probe the provider but to also empower the provider to 
answer their patients’ questions as the answers and information to each concern is 
available on the same WoW system the patient or their parent presents to them. By 
interviewing patient’s parents and providers, our study aims to evaluate whether the 
interaction with the provider worked by assisting both patient parents and providers in 
bringing up HPV, the HPV vaccine, and addressing concerns. Through the WoW system, 
the study aims to analyze how to empower providers and increase provider knowledge 
about HPV and the HPV vaccine to be comfortable enough to offer the vaccine and 
educate patients enough about the vaccine. By using the WoW website to identify the 
concerns that patients have and link the benefits of each concern with factual information 
relating to that concern, providers no longer have to worry about coming up with answers 
using the knowledge they have immediately at hand as answers are provided to them on 





This study is a one-armed proof of concept pilot trial among 27 urban parent/child 
dyads to evaluate the effects of a motivational and educational intervention, the Brief 
Negotiated Interview (BNI), followed by a set of educational text messages that are 
aimed to increase HPV vaccination uptake and completion rates among child participants 
and thus decrease cervical cancer rates. The BNI uses a client-based motivational 




 This one-arm pilot study was conducted at Boston Medical Center (BMC), a large 
urban academic hospital in Boston, Massachusetts. Participants were recruited from 
clinics operated by the Departments of Pediatrics and Adolescent Medicine. BMC serves 
a predominantly low-income, minority population with roughly 57% of patients coming 
from under-served populations. The Pediatric Clinic sees approximately 4,000 patients 
ages 9-17 annually. These patients are racially and ethnically diverse (62% Black, 15% 
White, 13% Latino and 10% other), and for the most part socioeconomically 





 Parents that appeared to be accompanying children between the ages of 9 and 17 
years of age were approached and asked about their interest in participating in the study. 
Parents were then asked questions to determine if they met the eligibility requirements. 
To meet the study’s requirements, participants must have a child between the ages of 9 
and 17, be their parent or legal guardian, be the individual who allowed medical 
providers to administer vaccines to the child, understand (speak, read, and write) English 
fluently, and their child must have only either received no doses or one dose of the HPV 
vaccination series. After completion of the interview, participants were asked to sign up 
for the WoW system which included checking off concerns they had about cervical 
cancer, oropharynx cancer, and the HPV vaccine that they would show to their provider 
during their child’s appointment to facilitate communication. Participants also answered a 
questionnaire to determine their initial knowledge on cervical cancer, oropharynx cancer, 
their previous knowledge on the HPV vaccine, and their opinions on the HPV vaccine.  
 
Recruitment and Data Collection  
The mobile system used to identify initial participant concerns and used for 
follow-up after enrollment, the WoW system, is an automated texting program that 
provides both educational and reminding text messages to participants. Through using the 
WoW system as a cost-effective way to offer parent participants knowledge about HPV, 
the HPV vaccine, and cervical cancer screening, the system aims to ultimately increase 
motivation for HPV vaccination and cervical cancer screening which would better adhere 
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to current HPV vaccination and cervical cancer screening guidelines. Combining both the 
BNI and the WoW system creates an integrated intergenerational model stemming from a 
Health Belief Model of perceived susceptibility and severity. This paper specifically 
focused on the viability of the WoW system in improving patient-provider 
communication evaluated based on HPV vaccination. 
 Eligibility criteria for participation within this study are as follows: First, the adult 
participant had to have a child between the ages of 9 to 17 years that was receiving care 
at either the Pediatrics or Adolescent Departments of Boston Medical Center. Second, the 
adult participant had to be able to read, write, and understand English proficiently. Third, 
neither the adult participant nor their child (if female) could be pregnant at the time of 
enrollment. Fourth, the participant’s child had to either not have initiated the HPV 
vaccination series or only received one shot within the series.  
 As of August 2018, parents of children between the ages of 9 and 17 years of age 
in the Pediatrics and Adolescent department of BMC were first screened by upcoming 
appointment date and child age by using BMC’s EPIC computer system. All physicians 
within the Pediatric and Adolescent Departments of BMC gave their consent for the 
study to contact their patients. Families with children between that ages of 9-17 years of 
age were mailed a brief letter containing a summary of the study and stating that they 
may be approached to join the study prior to their appointment. Some families were also 
called in advance of their appointment to ask of their interest in the study.  
Prior to child’s appointment time at BMC while waiting to be admitted in the 
pediatric and adolescent waiting rooms, parents accompanying their children to their 
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appointments were approached. After being initially approached and agreeing to 
participate, parents were read the informed consent form and a research assistant 
proceeded to assist parents in signing up for the WoW program as well as proceeding 
through a 15-minute questionnaire. Research assistants administered a screening 
questionnaire to collect demographic information, thoughts, knowledge, attitudes, and 
concerns about HPV vaccination and Cervical Cancer Screening. Information about HPV 
vaccine administration and Cervical Cancer Screening history was obtained from the 
adult guardian and child during the baseline questionnaire and verified using the 
hospital’s electronic medical record system, EPIC. All interviews were done in person to 
determine if families were eligible for participation. The research assistant then entered 
this information into an online data collection tool, REDcap, and into the WoW system. 
WoW was developed by an external contractor with guidance from the study team. WoW 
contained registration of the adult guardian profile and included demographics, contact 
information, HPV vaccine concerns, Cervical Cancer Screening Concerns, daughter’s 
HPV vaccine history, Cervical Cancer Screening history of female adult participants, and 
future appointment information for both parent and their child.  
A second questionnaire was administered following the child’s appointment to 
ask about different aspects of WoW and determine if WoW had helped facilitate 
conversation about the HPV vaccine and its related effects. Questionnaires were either 
completed completely in person or participants were called following their appointment 
for questionnaire completion. All parents received a 10-dollar gift card as an incentive for 
their initial signing up within the WoW system and completion of the first two 
	
19 
questionnaires. Providers of the participants were then interviewed to determine their 
opinions on the WoW system and if they believed the system helped facilitate 
communication on the different aspects of the HPV vaccine. The Institutional Review 
Board (IRB) at BMC approved the study. 
 
Data Analysis 
  The data collected from study participants was entered into an online data 
collection tool, REDcap, to organize all information collected. Information collected 
included data collected by the WoW system with regards to participant demographics, 
contact information, HPV vaccine and Cervical Cancer Screening information, and a 
texting log that recorded all text messages sent to participants. Following the intervention, 
participants either filled out in person or were called by a research assistant to fill out a 
follow-up questionnaire about WoW. The follow-up questionnaire was designed to assess: 
1) whether or not the website was user friendly, 2) how helpful WoW was in increasing 
the confidence of the participants in their knowledge about HPV screening and 








In our recruitment process, researchers approached roughly 250 patients that 
appeared to fit the eligibility requirements of this study. As of the writing of this paper, a 
total of 27 dyads (totaling 54 participants) met inclusion criteria and were enrolled within 
this study. Demographic characters of participants are described in Table 2. The mean 
age of the adult caregiver was 38 years old plus or minus 6.7 years, and the child’s mean 
age was 11 years old plus or minus 1.8 years. With regards to the recruited adult 
caregivers, 48% of the recruited caregivers were female whereas 52% of the recruited 
caregivers were male. Demographic distribution of participating adult caregivers found 
that over 70% of the sample were African American. The primary language spoken by 
adult participants was English (85%), and the majority of adult participants were born in 
the United States (67%). There was an equal amount of adult caregivers who reported 
completing high school or receiving their GED with the amount of adult caregivers who 
reported either some or having completed college or university with 46% of participants 
in each category. Overall, a majority of the parents reported receiving health information 
from their clinician (70%) while the Internet/Google came in as a high second choice 
(52%). All adults reported having insurance. 
With regards to the adult participants’ children, over 50% of the children recruited 
were female, with 57% of the children female and 43% of the children male (Table 2). 
Demographic distribution of the participants’ children also found that over 70% of the 
sample were African American, and an even greater majority of the participants’ children 
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spoke English as their primary language (95%). Though every parent participant 
possessed a cell phone as required to enroll within the study, only 36% of the child 
participants reported owning a cellphone. Similar to their parents, the participants’ 
children as a majority also reported receiving health information from their clinician 
(65%) though Family/Friends was reported as the second highest choice (43%). 
 




Table 2. Demographic Information of Study Participants continued 
 
*Four child records were not completed so sample size of child data reported is 4 less 
than sample size of parent data reported. 
 
HPV Knowledge and Attitudes 
 The majority of caregiver participants (80%) had heard of the HPV vaccine 
(Table 3). However, while of the majority of parents had heard of the HPV vaccine 
however, the majority of parents also demonstrated low knowledge of HPV and its 
effects on the body. Most parents had heard of the HPV vaccine from their doctor at 56% 
reporting having done so, with 22% reporting they had been exposed by the media to the 
HPV vaccine as the second highest choice. Very few parents reported having heard of the 
HPV vaccine from social media, the internet, or family and friends (7%, 11%, and 11% 
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respectively). Seventy-six percent of caregivers reported they would get the HPV vaccine 
for their child and 80% of caregivers even said that getting the HPV vaccine for their 
child was important to them, however only 48% reported thinking that the HPV vaccine 
was safe while the remaining 52% reported not knowing (Table 4). 64% of parents 
reported having ever had HPV testing for themselves. 
Table 3. Parent's Knowledge about the HPV Vaccine 
 
Only 44% of adult participants believed that HPV could cause cervical cancer 
while another 44% of adult participants were unsure (Table 4). Similarly, only 32% of 
adult participants believed that HPV could cause oral cancer while another 56% of adult 
participants were unsure. With regards to HPV infection, only 28% of caregiver 
participants believed that HPV could be passed on by genital skin-to-skin contact though 
a little over half (52%) believed that HPV could be passed on during sexual intercourse. 
Only 32% of participants believed that most sexually active people will get HPV at some 





Table 4. Parent's Attitudes towards and Beliefs about the HPV Vaccine 
 
Knowledge of HPV among the participant’s children was overall low compared to 
that of the parents (Table 5). Only 27% of children had heard of HPV and 9% knew that 
HPV can cause cervical cancer. An even lower percentage of children (5%) knew that 
HPV can be passed by genital skin-to-skin contact though 9% believed that HPV can be 
passed on during sexual intercourse. With regards to participant child knowledge about 
the HPV vaccine based on statements about HPV, the most commonly reported answer to 




Table 5. Child’s Attitudes towards and Beliefs about the HPV Vaccine 
 
Cervical Cancer and Cervical Cancer Screening Attitudes and Knowledge 
 A large majority (77%) of caregiver participants had heard of cervical cancer, but 
only 54% believed that people could die from cervical cancer and a little under a quarter 
(24%) knew someone with cervical cancer (Table 6). In addition, despite 73% of 
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participants reporting knowing what the cervix is, 46% of participants still believed that 
both men and women could get cervical cancer.  
 








WoW Feedback from Parent Participants 
Overall, parent participants who participated in the initial follow-up questionnaire 
for the WoW system reported a positive experience to WoW with 81% of participants 
either strongly agreeing or agreeing that the WoW website was easy to understand (Table 
7). Despite 92% of participants reporting that the WoW website was helpful for 
communicating their health concerns with their provider however, only 52% of 
participants reported having shown their providers their health concerns through the 
WoW system and only half reported that providers discussed all of their selected 
concerns with them at their child’s appointment.  
Table 7. Parent’s Initial WoW Feedback 
 
 
WoW Feedback from Provider Surveys 
Out of the seven providers from the Adolescent Clinic at Boston Medical Center 
that we interviewed, none of the providers reported having their patients’ parents show 
the WoW website to them at appointments (Table 8). Three of the participants under 
these providers reported that they had shown their physician the WoW website at their 
Strongly Agree Agree Neutral Disagree Strongly Disagree
10/25 (40%) The WoW Website was easy to sign up for 15/23 (65%) 8/23 (35%) 0/23 (0%) 0/23 (0%) 0/23 (0%)
10/25 (40%) The WoW website is easy to use 11/23 (48%) 9/23 (39%) 3/23 (13%) 0/23 (0%) 0/23 (0%)
The WoW website is easy to understand 10/23 (43%) 11/23 (48%) 2/23 (9%) 0/23 (0%) 0/23 (0%)
The WoW website is helpful for communicating my health concerns with my provider 9/12 (75%) 2/12 (17%) 1/12 (8%) 0/12 (0%) 0/12 (0%)
My provider answered all of my health questions and concerns in a way that was easy to understand 7/12 (58%) 5/12 (42%) 0/12 (0%) 0/12 (0%) 0/12 (0%)
Yes No No concerns
Did you use the WoW system to show your provider your chosen health concerns? 12/23 (52%) 9/23 (39%) 2/23 (9%)
All Most Some About Half None
How many of your selected concerns did you provider discuss with you? 6/12 (50%) 2/12 (17%) 1/12 (8%) 3/12 (25%) 0/12 (0%)






child’s appointment, however none of the providers acknowledge receiving or the patient 
sharing the tablet or smartphone with them. In addition, no providers interviewed 
reported the parent participants of their patients approaching them first with HPV-related 
health concerns. After being told a brief description of the WoW system and its intended 
use, providers reported that discussing concerns of HPV vaccine hesitancy with parents 
who have not expressed concerns might increase resistance for HPV vaccination. 
Providers also reported not having time during a clinical visit to check other additional 
websites in addition to reviewing the electronic medical records system (EMR), EPIC, 
and entering their chart notes. One provider quotes, “I think the WoW website is very 
unnecessary because electronic EMR already shows all of these things. Too many 
applications just gives a higher chance that both patients and doctors will be less 
compliant because there’s just too much for to keep track of all these separate things.” 
This shows how providers expressed that parallel systems are not a good use of time and 
effort and resources, and so the uses of the WoW system would be better embedded in an 
everyday existing workflow. Other general themes from provider interviews showed that 
providers felt that they were already including the HPV vaccine as part of a regular 
vaccination schedule they administered to their patients, making the WoW system even 







Table 8. Provider Survey 
 
 
HPV Vaccine Uptake 
Of the 27 participants enrolled in the study, 6 participants did not initiate the 
vaccine series because they were not yet due for the first dose and one participant did not 
initiate the vaccine despite being due for the first dose (aged 15). Of the 12 participants 
who had at least one dose of the vaccine prior to enrollment, 9 of these participants (75%) 
completed the HPV vaccine series during the study. All of the children who completed 
their vaccination series through the study were within the age range of 9-14 years. Of the 
8 participants who initiated their HPV vaccine series through this study (8/27, 30%), 7 of 
the participants were not yet due for the second dose by the writing of this paper and 1 
participant was overdue for their second vaccine dose. Out of the 8 children who initiated 
their HPV vaccine series through this study, one child fell within the age range of 15-17 
and therefore could not be expected to finish their vaccination series within this study as 
children 15 years and above require a three-dose vaccination series rather than the two-
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dose vaccination series that children 9-14 years would receive. Overall, the percentage 
for completion will be based on the 21 children who received intervention and had 
initiated their vaccine series or were due for the vaccine as this study cannot predict the 
impact of the intervention on the vaccine uptake for the 6 participants who were not yet 
due for the vaccine. As a result, the percentage of vaccine completion as of the writing of 





















This study is among the first to utilize a Brief Negotiated Interview (BNI) to 
address the concerns of parents related to HPV and HPV vaccination, to empower parents 
to make health-promoting decisions, and to promote shared-decision making between 
patients and their providers. While recent studies have shown that BNI can significantly 
increase knowledge of the HPV vaccine and increase the initiation rate for the HPV 
vaccine, these studies have also shown that a BNI alone still fails to ensure a higher HPV 
vaccination series completion rate (Joseph et al., 2016). Ultimately, this one-armed pilot 
study tested the addition of a website system to assist and empower patients and their 
parents in identifying their concerns. Through this system, this study aimed to better 
facilitate patient-provider communication and consequently improve HPV vaccine 
completion rates. 
Study findings showed mixed reviews from parent participants and providers on 
the effectiveness of the WoW website in facilitating patient and provider communication 
on the different aspects of HPV vaccination and affecting parents’ decisions to vaccinate 
their children. Based on the WoW feedback collected from the initial survey on the WoW 
system completed by parent participants, the mobile health information technology 
system was widely acceptable in terms of ease in usage and with the overwhelming 
majority of parents (92%) reporting that they either agreed or strongly agreed that the 
WoW website is helpful for communicating their health concerns with their provider. 
Despite the high percentage of parents who reported that the WoW website was helpful 
for communicating their health concerns with their provider however, only 52% reported 
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using the WoW system to show their provider their chosen health concerns. This suggests 
that parents may not have necessarily used their smart device to display the WoW system 
to show their providers their concerns, but instead may have been prompted by the list of 
concerns within the WoW system to bring up HPV and HPV vaccine related questions to 
their providers. 
Despite the initial positive feedback from parent participants on the WoW system 
and how it helped communicate their health concerns with their providers however, none 
of the seven providers from the Pediatrics and Adolescent Clinics interviewed reported 
having been presented the WoW website by parent participants and none of the seven 
providers interviewed reported having even been first approached by parents to discuss 
HPV-related health concerns. However, five of the seven providers (71%) did report that 
upon the topic of HPV and the HPV vaccine being brought up within the appointment, 
that they were able to discuss all of their patient’s HPV-related health concerns with them. 
This report suggests that while parents may not yet feel comfortable or empowered by the 
information provided through the WoW system enough to initiate conversations about 
their HPV-related health concerns, that they are able to express their concerns and have 
them answered once the topic of HPV-related health concerns is brought up in the 
appointment by their provider. Alternatively, parents may have become more well 
informed and did not see a need to approach their child’s provider with their concerns 
after reading the responses to their concerns on the WoW system and learning from the 
information presented. Parents may have also simply forgot to show their provider the 
WoW system on their tablet or smartphone. Based on analysis of the interviews 
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conducted, the general themes from the interview were that WoW was time consuming 
and inefficient due to providers’ views that it was a parallel system to the already existing 
workflow they had.  
As of this secondary stage of the study, seven participants (26%) were found to 
have not initiated the HPV vaccine series, six of whom appeared as not due for their first 
dose of the HPV vaccine on their electronic medical records system. This suggests that 
although participants may have been open or intended to vaccinate during the study 
period, that their provider was not prompted to do so through the records system. 
Through the seven provider interviews conducted as of this paper, it has also been shown 
that none of the providers themselves had conversations about the HPV vaccine initiated 
by their patient or patient’s parent. As a result, this highlights the importance of 
prompting providers to vaccinate and follow HPV vaccine guidelines as the reports from 
the study show that neither patient nor parent of the patient have yet been the prompter 
for providers to vaccine. 
 As reported in the HPV Vaccine Uptake section in the Results, a third of 
participants (33%) completed the HPV vaccine series and an additional almost third of 
participants (30%) initiated their HPV vaccine series through this study. This study 
determined that of the 12 participants who had at least one dose of the vaccine prior to 
enrollment, 75% of these participants completed the HPV vaccine series during the study. 
Based on the initiation and completion statistics outcome reported, this shows great 
potential for the use of the BNI coupled with the WoW system to help improve rates of 
initiation and completion of HPV vaccination going forward as the intervention may have 
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either helped encourage parents to either initiate vaccination or complete their child’s 
previously started series. This exhibits how further studies should explore innovative 
ways of empowering patients to prompt providers to facilitate more communication 
between patients and their providers as well as improvements to technology to enhance 
provider recommendation of the HPV vaccine in order to promote an increase in HPV 
vaccine completion.  
It was also shown in the Results section that though parents have heard of the 
HPV vaccine, that there is still a very large gap in HPV risk, cervical cancer risk, and 
HPV vaccine related knowledge. Parents have especially low knowledge about HPV 
transmission about the HPV infection. This would translate into low motivation to 
vaccinate which also reflects a gap in knowledge and a great need in educating parents. 
Future studies should also explore the following: how to integrate web-based Health 
information technology as WOW with patient electronic medical record to facilitate and 
strengthen patient-provider communication and provider recommendation; how to best 
increase the effectiveness of providers’ HPV vaccine recommendations by identifying the 
provider, parent/patient, and practice-level characteristics that may enhance or inhibit 
vaccine uptake among children 11-12 in the U.S. Furthermore, as it was previously 
reported that both HPV vaccination rates and cervical cancer screening rates are low 
within young adults, future studies should explore ways to improve vaccination rates 





 This study is a one-arm pilot study with a small sample size and no comparison 
group which makes the results of this study overall non-generalizable. In addition, for the 
purpose of this paper, not all 30 intended participants were able to be recruited as of the 
writing of this paper which contributes to the small sample size. Due to a limited study 
timeline, this rate does not take into account possible vaccination post-study. Follow-up 
calls to participants to complete surveys also posed several challenges during the course 
of the study due difficulty in communication attributed to a limited amount of time 
expressed by participants and phone service changes or disconnections. These limited the 
generalizability of WoW Survey results as, but a strength of the study was access to 
clinical electronic record documentation of HPV vaccination and cervical cancer 
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